First Time Loading...

Panacea Biotec Ltd
NSE:PANACEABIO

Watchlist Manager
Panacea Biotec Ltd Logo
Panacea Biotec Ltd
NSE:PANACEABIO
Watchlist
Price: 132.7 INR -0.3% Market Closed
Updated: May 12, 2024
Section:
 

Wall Street
Price Targets

PANACEABIO Price Targets Summary
Panacea Biotec Ltd

Wall Street analysts forecast PANACEABIO stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PANACEABIO is 69 INR .

PANACEABIO Lowest Forecast
Wall Street Target
Not Available
PANACEABIO Average Forecast
Wall Street Target
69 INR
48% Downside
PANACEABIO Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
69 INR
48% Downside
Highest
Price Target
Not Available
Panacea Biotec Ltd Competitors:
Price Targets
6855
Ascentage Pharma Group International
51% Upside
CRBU
Caribou Biosciences Inc
476% Upside
9995
RemeGen Co Ltd
49% Upside
A
ALVO
Alvotech SA
26% Upside
6855
Ascentage Pharma Group International
51% Upside
CRBU
Caribou Biosciences Inc
476% Upside
9995
RemeGen Co Ltd
49% Upside
A
ALVO
Alvotech SA
26% Upside
IMCR
Immunocore Holdings PLC
48% Upside
Z
ZURA
Zura Bio Ltd
292% Upside
AVCT
Avacta Group PLC
85% Upside
2INV
2Invest AG
71% Downside

Revenue
Forecast

Revenue Estimate
Panacea Biotec Ltd

Revenue forecast
is not available for
Panacea Biotec Ltd

Operating Income
Forecast

Operating Income Estimate
Panacea Biotec Ltd

Operating Income forecast
is not available for
Panacea Biotec Ltd

Net Income
Forecast

Net Income Estimate
Panacea Biotec Ltd

Net Income forecast
is not available for
Panacea Biotec Ltd

See Also

Summary
PANACEABIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
PANACEABIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PANACEABIO stock valuation using valuation multiples.
Wall Street Estimates
PANACEABIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PANACEABIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PANACEABIO's stock price target?
Price Target
69 INR

According to Wall Street analysts, the average 1-year price target for PANACEABIO is 69 INR .

ALPHA SPREAD
Join more than 136,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.